COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence
Authors:
- 1 November 2021
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (5) , 1274-1284
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- COVID-19: A review of therapeutic strategies and vaccine candidatesClinical Immunology, 2021
- The Covid-19 Vaccine-Development MultiverseNew England Journal of Medicine, 2020
- The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine FormulationAAPS PharmSciTech, 2020
- The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization StrategiesFrontiers in Immunology, 2020
- Development of therapeutic antibodies for the treatment of diseasesJournal of Biomedical Science, 2020
- mRNA vaccines — a new era in vaccinologyNature Reviews Drug Discovery, 2018
- Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reportsVaccine, 2017
- Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated DiseasesJAMA, 2012
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral responseAnnals of the Rheumatic Diseases, 2008